Vaxart granted extension by Nasdaq to regain compliance

Vaxart (VXRT) received a decision letter from the Nasdaq Hearings Panel on August 27, 2025, granting the Company’s request to effect a plan to regain compliance with The Nasdaq Stock Market’s minimum bid price requirement. The grant of the Company’s request for continued listing on Nasdaq is subject to the following conditions: On or before September 5, 2025, the Company shall obtain stockholder approval for a reverse stock split; On or before October 6, 2025, the Company shall complete a RSS; and On or before October 17, 2025, the Company shall demonstrate compliance with Nasdaq Listing Rule 5550(a)(2). At the hearing, held on August 14, 2025, Vaxart’s senior management, advisors and outside counsel outlined the Company’s background and compliance plan for the Panel. With respect to its Bid Price Rule deficiency, the Company highlighted changes to its RSS proposal, including narrowing the proposed range for the RSS ratio, reducing the number of authorized shares, and a communication plan to gain the support of stockholders.